| Identification | Back Directory | [Name]
4-Piperidinesulfonamide, 1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]- | [CAS]
2260969-36-4 | [Synonyms]
Selnoflast
Selnoflast (RG 6418)
4-Piperidinesulfonamide, 1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]- | [Molecular Formula]
C20H29N3O3S | [MOL File]
2260969-36-4.mol | [Molecular Weight]
391.53 |
| Chemical Properties | Back Directory | [density ]
1.30±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 12.5 mg/mL (31.93 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
-0.05±0.20(Predicted) | [color ]
White to off-white | [InChI]
InChI=1S/C20H29N3O3S/c1-2-23-11-9-16(10-12-23)27(25,26)22-20(24)21-19-17-7-3-5-14(17)13-15-6-4-8-18(15)19/h13,16H,2-12H2,1H3,(H2,21,22,24) | [InChIKey]
OHIFQOUPTWBQLE-UHFFFAOYSA-N | [SMILES]
N1(CC)CCC(S(NC(NC2=C3C(=CC4CCCC2=4)CCC3)=O)(=O)=O)CC1 |
| Hazard Information | Back Directory | [Uses]
Selnoflast (RO7486967), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease[1][2][3]. | [IC 50]
NLRP3 | [References]
[1] Klughammer B, et al. A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin Transl Med. 2023 Nov;13(11):e1471. DOI:10.1002/ctm2.1471
[2] Vande Walle L, et al. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2023 Nov 29. DOI:10.1038/s41573-023-00822-2
[3] Silvis MJM, et al., NLRP3-Inflammasome Inhibition with IZD334 Does Not Reduce Cardiac Damage in a Pig Model of Myocardial Infarction. Biomedicines. 2022 Nov 28;10(12):3056. DOI:10.3390/biomedicines10123056 |
|
|